secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0000950170-23-053547
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Impel Pharmaceuticals receives Nasdaq delisting notice for failure to meet MVLS/MVPHS minimums
--------------------------------------------------------------------------------

- Nasdaq notified Impel on Oct 10, 2023, that it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.
- Trading suspension of common stock (IMPL) set for Oct 19, 2023, unless company requests hearing.
- Impel intends to appeal the delisting determination and request a hearing before a Nasdaq Hearings Panel.
- Appeal would automatically stay suspension pending the Panel's decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023053547/0000950170-23-053547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023053547/impl-20231010.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer